Over the course of the BRAINTEASER project, the consortium developed and integrated a comprehensive set of tools and models aimed at transforming the care pathway for ALS and MS patients. Key achievements include:
- AI-based models for patient stratification, progression prediction, and risk assessment, capable of integrating clinical, sensor, and environmental data.
- A patient mobile app enabling self-reporting, continuous feedback, and remote symptom tracking, and a clinical dashboard for monitoring patients and supporting timely interventions.
- A data infrastructure ensuring secure, GDPR-compliant data management and interoperability, supporting long-term sharing in alignment with FAIR principles.
- An AI simulation platform integrated with InSilicoTrials to support in silico clinical research and regulatory engagement.
- An open Community of Practice (CoP) bringing together patients, caregivers, clinicians, and researchers to foster exchange, learning, and dissemination.
Throughout the project, dissemination was actively pursued through scientific publications, open challenges, policy dialogues, and public events. Over 40 open-access papers, 3 public data challenges, and multiple stakeholder engagements were conducted. Patient associations and clinicians contributed to co-design and validation activities, increasing relevance and trust.
In the final period, efforts focused on delivering key strategic outputs:
- Exploitation plans and business models for key innovations (e.g. AI tools, apps, platform services).
- Public health recommendations on digital transformation in care delivery.
- Roadmaps for certification of software as medical device (SaMD).
- The final update of the Data Management Plan and alignment with EOSC and long-term data reusability.
BRAINTEASER outcomes are currently being adopted or evaluated for real-world use and are well-positioned for continued impact in both clinical and industrial settings.
